Safety and Efficacy of Biologic Agents for the Management of Inflammatory Bowel Disease After Liver Transplantation

Publisher： John Wiley & Sons Inc

E-ISSN： 1875-9114|37|12|1578-1585

ISSN： 0277-0008

Source： PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol.37, Iss.12, 2017-12, pp. : 1578-1585

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recurrence of autoimmune liver disease and inflammatory bowel disease after pediatric liver transplantation

By  

LIVER TRANSPLANTATION, Vol. 22, Iss. 9, 2016-09 ,pp. : 1275-1283

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antitumor necrosis α treatment in primary sclerosing cholangitis associated inflammatory bowel disease after liver transplantation

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 11, 2015-11 ,pp. : 1455-1456

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of anti‐TNF therapy in elderly patients with inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 4, 2015-08 ,pp. : 441-451

John Wiley & Sons Inc

Access to resources Recommend Favorite

Market share and costs of biologic therapies for inflammatory bowel disease in the USA

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 3, 2018-02 ,pp. : 364-370

John Wiley & Sons Inc

Access to resources Recommend Favorite

The safety and efficacy of proximal splenic artery embolization after liver transplantation are still not clearly defined

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 4, 2015-04 ,pp. : 417-418

John Wiley & Sons Inc

Access to resources Recommend Favorite